SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02869360
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
Pilot Study of Positron Emission Tomography (PET) Imaging: Correlations With Advanced Magnetic Resonance Imaging in Multiple Sclerosis
Traditional Magnetic Resonance Imaging (MRI) in Multiple Sclerosis (MS) has enabled clinicians to measure disease activity but there are inherent limitations. Clinical/radiographic dissociation can be seen in some patients and the abnormalities are not specific. This pilot study is an opportunity to determine the relationship between quantitative advanced MRI measures and OCT with PET measurements of microglial activation and myelin health.
NCT02869360 Multiple Sclerosis MeSH:Multiple Sclerosis Sclerosis
Primary Outcomes
Measure: Whole Brain PBR28 binding Time: BaselineSecondary Outcomes
Measure: Lesional PiB binding Time: BaselineMeasure: Myelin Water Imaging Time: Baseline
Measure: MR Spectroscopy (Total NAA, NAA/Cr, mI) Time: Baseline
Measure: Optical Coherence Tomography (RNFL thickness) Time: Baseline
Time Perspective: Prospective
Cohort
There is one SNP
SNPs
1 rs6971
- Aged 18 to 60 - High or mixed affinity binder to rs6971 TSPO polymorphism Exclusion Criteria: - Pregnant or breastfeeding - Suffering from an unstable medical condition - Have a neurological or ocular disorder other than MS - Any contra-indications to MRI Inclusion Criteria: - Diagnosed with Multiple Sclerosis according to the 2011 McDonald criteria.
- Aged 18 to 60 - High or mixed affinity binder to rs6971 TSPO polymorphism Exclusion Criteria: - Pregnant or breastfeeding - Suffering from an unstable medical condition - Have a neurological or ocular disorder other than MS - Any contra-indications to MRI Multiple Sclerosis Multiple Sclerosis Sclerosis null